Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study.
Datta-Mannan A, Moser B, Xu W, Jackson K, Witcher J, Armstrong AW, Blauvelt A, Lio PA. Datta-Mannan A, et al. Among authors: lio pa. Clin Ther. 2025 Jan;47(1):55-61. doi: 10.1016/j.clinthera.2024.10.016. Epub 2024 Dec 4. Clin Ther. 2025. PMID: 39638723 Free article. Clinical Trial.
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
Simpson E, Fernández-Peñas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, Agell H, Casillas M, Ding Y, Yang FE, Pierce E, Bieber T. Simpson E, et al. Among authors: lio pa. Adv Ther. 2024 Dec 5. doi: 10.1007/s12325-024-03010-9. Online ahead of print. Adv Ther. 2024. PMID: 39636571 No abstract available.
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
Simpson E, Fernández-Peñas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, Agell H, Casillas M, Ding Y, Yang FE, Pierce E, Bieber T. Simpson E, et al. Among authors: lio pa. Adv Ther. 2024 Sep 9. doi: 10.1007/s12325-024-02974-y. Online ahead of print. Adv Ther. 2024. PMID: 39249591
Complementary and Alternative Therapies for Psoriasis.
Chalupczak NV, Lio PA. Chalupczak NV, et al. Among authors: lio pa. Arch Dermatol Res. 2024 Aug 17;316(8):531. doi: 10.1007/s00403-024-03279-4. Arch Dermatol Res. 2024. PMID: 39154058 Review.
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
Lio PA, Armstrong A, Gutermuth J, Nosbaum A, Sofen H, Gil EG, Casillas M, Chen S, Sun L, Pierce E, Elmaraghy H, Dawson Z, Torres T. Lio PA, et al. Dermatol Ther (Heidelb). 2024 Jul;14(7):1929-1943. doi: 10.1007/s13555-024-01199-9. Epub 2024 Jun 26. Dermatol Ther (Heidelb). 2024. PMID: 38922484 Free PMC article.
142 results